Clinical Trial Update: A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases [Phase 3]

View source ↗

Summary

Phase III trial of ZD4054 (Zibotentan) in hormone-resistant prostate cancer with bone metastases completed; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ZD4054 (Zibotentan) (zibotentan)

Snippet

Sponsor: AstraZeneca | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2012-05-31